TY - JOUR
T1 - Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction
AU - Amado, Luciano C.
AU - Saliaris, Anastasios P.
AU - Schuleri, Karl H.
AU - St. John, Marcus
AU - Xie, Jin Sheng
AU - Cattaneo, Stephen
AU - Durand, Daniel J.
AU - Fitton, Torin
AU - Kuang, Jin Qiang
AU - Stewart, Garrick
AU - Lehrke, Stephanie
AU - Baumgartner, William W.
AU - Martin, Bradley J.
AU - Heldman, Alan W.
AU - Hare, Joshua M.
PY - 2005/8/9
Y1 - 2005/8/9
N2 - Although clinical trials of autologous whole bone marrow for cardiac repair demonstrate promising results, many practical and mechanistic issues regarding this therapy remain highly controversial. Here, we report the results of a randomized study of bone-marrow-derived mesenchymal stem cells, administered to pigs, which offer several new insights regarding cellular cardiomyoplasty. First, cells were safely injected by using a percutaneous-injection catheter 3 d after myocardial infarction. Second, cellular transplantation resulted in long-term engraftment, profound reduction in scar formation, and near-normalization of cardiac function. Third, transplanted cells were preprepared from an allogeneic donor and were not rejected, a major practical advance for widespread application of this therapy. Together, these findings demonstrate that the direct injection of cellular grafts into damaged myocardium is safe and effective in the periinfarct period. The direct delivery of cells to necrotic myocardium offers a valuable alternative to intracoronary cell injections, and the use of allogeneic mesenchymal stem cells provides a valuable strategy for cardiac regenerative therapy that avoids the need for preparing autologous cells from the recipient.
AB - Although clinical trials of autologous whole bone marrow for cardiac repair demonstrate promising results, many practical and mechanistic issues regarding this therapy remain highly controversial. Here, we report the results of a randomized study of bone-marrow-derived mesenchymal stem cells, administered to pigs, which offer several new insights regarding cellular cardiomyoplasty. First, cells were safely injected by using a percutaneous-injection catheter 3 d after myocardial infarction. Second, cellular transplantation resulted in long-term engraftment, profound reduction in scar formation, and near-normalization of cardiac function. Third, transplanted cells were preprepared from an allogeneic donor and were not rejected, a major practical advance for widespread application of this therapy. Together, these findings demonstrate that the direct injection of cellular grafts into damaged myocardium is safe and effective in the periinfarct period. The direct delivery of cells to necrotic myocardium offers a valuable alternative to intracoronary cell injections, and the use of allogeneic mesenchymal stem cells provides a valuable strategy for cardiac regenerative therapy that avoids the need for preparing autologous cells from the recipient.
UR - http://www.scopus.com/inward/record.url?scp=23844475067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23844475067&partnerID=8YFLogxK
U2 - 10.1073/pnas.0504388102
DO - 10.1073/pnas.0504388102
M3 - Article
C2 - 16061805
AN - SCOPUS:23844475067
SN - 0027-8424
VL - 102
SP - 11474
EP - 11479
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 32
ER -